Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Andersen Tawil Syndrome Treatment Market Snapshot (2023 to 2033)

The global Andersen Tawil syndrome treatment market is expected to surpass an impressive valuation of US$ 1.9 Billion in 2023 and is projected to reach US$ 4.2 Billion by 2033, with a CAGR of 8.26%

An increase in the prevalence of Andersen-tawil syndrome is expected to drive the growth of the market. The increasing focus of the government to prioritize drugs for the treatment of rare diseases may also propel the growth of the Andersen-Tawil syndrome market during the forecast period. The increasing participation of organizations to support the treatment and to create awareness is also expected to drive the growth of the market. The rising Research and Development investments by the key players in the Andersen-Tawil Syndrome Market are also expected to boost the growth of the market.

However, the lack of large clinical studies may restrict the growth of the Andersen-Tawil syndrome market. The shortage of healthcare expected in the Middle East & Africa and Latin America may restrain the growth of the Andersen-Tawil Syndrome market in this region. The drug acetazolamide is likely to help with muscle weakness attacks, as well as dichlorphenamide (brand name KEVEYIS, the only FDA-approved periodic paralysis treatment).

Report Attribute Details
Expected Market Value (2023) US$ 1.9 Billion
Anticipated Forecast Value (2033) US$ 4.2 Billion
Projected Growth Rate (2023 to 2033) CAGR 8.26%

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2018 to 2022 Andersen Tawil Syndrome Treatment Demand Analysis vs. Forecast 2023 to 2033

The market for Andersen Tawil Syndrome Treatment was worth US$ 1.4 Billion in 2018 while growing at a CAGR of 6.3%. The increasing focus of the government to prioritize drugs for the treatment of rare diseases and growing participation from various organizations to treat this disease has been pushing healthcare industries and manufacturers to come up with next-generation drugs like ‘Acetazolamide’ for treatment of Andersen Tawil syndrome.

These developments have provided a boost for this market. Considering these factors, demand for this market is projected to grow at a CAGR of 8.26%, reaching a valuation of US$ 4.2 Billion.

Which are Some Prominent Drivers of the Andersen Tawil Syndrome Treatment Market?

Mounting Research and development activities will propel the market expansion

Rising government funding for diagnostic procedures is likely to offer attractive opportunities for the Andersen-Tawil Syndrome diagnostic and treatment market which will lead to growth in product demand. The rising prevalence of disease, growing government initiatives, advancement in treatment options, genetic counseling, and increasing awareness of rare diseases are the factors that will expand the global Andersen disease treatment market.

Expanding Research and Development activities and the growing focus of major pharmaceutical companies toward novel treatment therapies will provide beneficial opportunities for the global Andersen disease treatment market in the forecast period of 2023 to 2033.

Moreover, the adoption of some of the more prominent diagnostic and treatment options including potassium supplements, molecular genetic testing, voluntary muscle contraction exercises, Holter monitoring, and electrocardiograms are anticipated to fuel market expansion.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What are the Challenges Projected to be Faced by the Market?

The high cost of treatment, slow growth in the adoption of novel drugs, and lack of awareness are the factors that will hamper the Andersen Tawil Syndrome Treatment market. Moreover, the availability of generic drugs is also expected to restrict market expansion.

Region-Wise Insights

North America dominates the market for Andersen Tawil Syndrome Treatment

North America dominates the Andersen disease treatment market due to the presence of major key players, advancement in treatment options, well-developed healthcare sector, rising prevalence of disease, and growing awareness towards health in this region.

Andersen Tawil Treatment market will witness great advancement in this region during the assessed time span. The improvement would be possible because of marketing examination instruments and because of existing players that are positively gotten comfortable with the market since the beginning.

Also, organization associations, associations, outcast chiefs, etc are channelizing their undertakings to make customer-driven things which will moreover add to the advancement in this locale. Increasing revenue, extended compensation, pattern setting advancement, and contraption, close by the tasks for spreading the thoughtfulness regarding the need will presumably make the Andersen Tawil therapeutics market grow tremendously.

South Asia to emerge as an Opportunistic Hub in Forthcoming Years

Andersen disease treatment market in South Asia is expected to grow during the forecast period due to the increasing research and development activities, increasing investment in the healthcare sector, emerging markets, and mounting government support.

South Asia is anticipated to experience the fastest growth in the Andersen-Tawil Syndrome market owing to improving healthcare infrastructure along with a rise in the number of cases suffering from the disease. In addition, increasing awareness may also help to fuel the growth of the Andersen-Tawil Syndrome market at a faster rate in this region. The developing private healthcare in countries like India is also expected to contribute to the growth of the Andersen-Tawil Syndrome market.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category wise Insights

Type 1 Andersen Tawil Syndrome Treatment dominating the segment growth

Type 1 Andersen Tawil Syndrome Treatment dominates the segment by disease type with a market share of around 59% and a segment CAGR of 5.4%. The growth is attributed as highest in this segment because type 1 disease is caused by a known KCNJ2 gene mutation making it easier to identify and commence the treatment of the disease. North America is anticipated to dominate the industry for Type 1 disease treatment followed by Europe during the forecast period.

The hospital segment is expected to dominate the market by distribution channel

Hospital pharmacies accounted for 55% market share in 2022, followed by Online pharmacies. This segment is expected to retain its dominance by end of 2033 owing to well-developed health infrastructure, rising government initiatives, and growing investments in innovating drugs for the treatment of Andersen Tawil Syndrome Treatment is likely to augment this segment growth and fuel the industry’s demand.

Start-ups in Andersen Tawil Syndrome Treatment Market

  • Founded in 2013, Lambda Health System is a developer of game-based robotic therapy for rehabilitation. The company is involved in the development of health systems that develops robotic equipment for assisted rehabilitation for people recovering from neurological injuries. It offers Lambda Robot, which is a rehabilitation device with 2 robotic arms. The arms have fixtures to hold the patient's legs and can adapt to a particular person. The company intends to make robotic rehabilitation a common theme in the treatment option for neural paraplegia. It has raised a total funding of US$ 31.2 K from ‘Venture Kick’.
  • Founded in 2008, Good Start Genetics is a molecular genetic information company based in Boston, US that offers carrier screening for inherited genetic diseases. The company provides genetic carrier screening tests for known and novel mutations that cause inherited genetic disorders. The company is using next-generation sequencing (NGS) and other proven genetic screening technologies for their genetic tests. Good Start Genetics provides carrier screening for all disorders recommended by the American Congress of Obstetricians and Gynecologists & the American College of Medical Genetics. It has two products: GeneVu for carrier testing and EmbryVu for embryo screening. Customers can order GeneVu through Amazon as well. It has raised funding of USD 32 million from CRG, Orbimed, Safeguard Scientifics, and 1 Other Investor.

Market Competition

Key players in the Andersen Tawil Syndrome Treatment Market are: Teva Pharmaceuticals Ltd, Zydus Pharmaceuticals, Inc., Sun Pharmaceuticals Industries Ltd., Advanz Pharmaceuticals, Novartis AG, Mylan N.V, Aurobindo Pharma, Dr. Reddy’s Laboratories Ltd., Viatris Inc, Pfizer Inc

Some recent developments in this market are:

  • In April 2021, Teva Pharmaceuticals was acquired by Karo Pharma Aktiebolag with the aim of gaining the European OTC brand portfolios and drug research including rare disease solutions. Also, Sun Pharmaceutical Industries Ltd. announced the acquisition of a 66% ownership interest in Trikaal Mediinfotech, and AWACS, through its subsidiary ABCD Technologies LLP.
  • In December 2016, Strongbridge Biopharma plc acquired U.S. commercialization rights for Keveyis from Taro Pharmaceutical Industries Ltd (a subsidiary of Sun Pharmaceutical Industries Ltd) for the treatment of periodic paralysis. Under the terms of the agreement, Taro Pharmaceutical Industries Ltd is to receive an upfront payment of US$ 8.5 Million and is also eligible to receive additional future payments upon the achievement of certain sales unit milestones. The acquisition of USA rights expands the company’s rare disease portfolio to include neuromuscular diseases.
  • In August 2015, Taro Pharmaceutical Industries Ltd received approval from the FDA for Keveyis (dichlorphenamide), an oral carbonic anhydrase inhibitor for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic, periodic paralysis, and related variants. The FDA approval of Keveyis is the most awaited, new, effective treatment option for many years for patients suffering from periodic paralysis.

Report Scope

Report Attribute Details
Market Value in 2023 US$ 1.9 Billion
Market Value in 2033 US$ 4.2 Billion
Growth Rate CAGR of 8.26 % from 2023 to 2033
Base Year for Estimation 2022
Historical Data 2018 to 2022
Forecast Period 2023 to 2033
Quantitative Units Revenue in US$ Billion and CAGR from 2023 to 2033
Report Coverage Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
  • Disease Type
  • Drug Type
  • Distribution Channel
  • Region
Regions Covered
  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa
Key Countries Profiled
  • USA
  • Canada
  • Brazil
  • Mexico
  • Germany
  • United Kingdom
  • France
  • Spain
  • Italy
  • India
  • Malaysia
  • Singapore
  • Thailand
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • GCC Countries
  • South Africa
  • Israel
Key Companies Profiled
  • Teva Pharmaceuticals Ltd
  • Zydus Pharmaceuticals, Inc.
  • Sun Pharmaceuticals Industries Ltd.
  • Advanz Pharmaceuticals
  • Novartis AG
  • Mylan N.V
  • Aurobindo Pharma
  • Dr. Reddy’s Laboratories Ltd.
  • Viatris Inc.
  • Pfizer Inc.
Customization Available Upon Request

Key Segments Profiled in the Andersen Tawil Syndrome Treatment Market Industry survey

Disease Type:

  • Type 1
  • Type 2

Drug Class:

  • Carbonic Anhydrate Inhibitors
  • Acetazolamide
  • Dichloropenamide
  • Antiarrhythmic Drugs
  • Amiodarone
  • Flecainide
  • Beta-Blockers
  • Atenolol

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Frequently Asked Questions

What is the Forecasted Growth Rate for the Global Anderson Tawil Syndrome Treatment Market?

The global market is forecasted to develop at an impressive 8.26% CAGR until 2033.

Which is the Net Worth of the Global Market for Anderson Tawil Syndrome Treatment Services?

The total demand in 2023 is estimated to generate a revenue of around US$ 1.9 billion.

What is the Growth Trend in South Asia in Adoption of Anderson Tawil Syndrome Treatment Services?

Rising government spending on healthcare infrastructure is driving the regional market at a faster rate.

Which End User Segment Creates a Higher Demand for Anderson Tawil Syndrome Treatment?

Hospital Pharmacies segment generated almost 55% of the total revenue in 2022.

Which Type of Anderson Tawil Syndrome Treatment is the Largest Segment in the Global Market?

Type 1 Anderson Tawil Syndrome created nearly 59% of the global demand in 2022.

Table of Content

1. Executive Summary | Andersen Tawil Syndrome Treatment Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033

        5.3.1. Type 1

        5.3.2. Type 2

    5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022

    5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033

6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug-class

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By Drug class, 2018 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug class, 2023 to 2033

        6.3.1. Carbonic Anhydrate Inhibitors

        6.3.2. Acetazolamide

        6.3.3. Dichlorpenamide

        6.3.4. Antiarrhythmic Drugs

        6.3.5. Amiodarone

        6.3.6. Flecainide

        6.3.7. Beta-Blockers

        6.3.8. Atenolol

    6.4. Y-o-Y Growth Trend Analysis By Drug class, 2018 to 2022

    6.5. Absolute $ Opportunity Analysis By Drug class, 2023 to 2033

7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel

    7.1. Introduction / Key Findings

    7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022

    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033

        7.3.1. Hospital Pharmacy

        7.3.2. Retail Pharmacy

        7.3.3. Online Pharmacy

    7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022

    7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033

8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region

    8.1. Introduction

    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022

    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        8.3.1. North America

        8.3.2. Latin America

        8.3.3. Europe

        8.3.4. South Asia

        8.3.5. East Asia

        8.3.6. Oceania

        8.3.7. Middle East and Africa(MEA)

    8.4. Market Attractiveness Analysis By Region

9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. USA

            9.2.1.2. Canada

        9.2.2. By Disease Type

        9.2.3. By Drug-class

        9.2.4. By Distribution Channel

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Disease Type

        9.3.3. By Drug-class

        9.3.4. By Distribution Channel

    9.4. Key Takeaways

10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Brazil

            10.2.1.2. Mexico

            10.2.1.3. Rest of Latin America

        10.2.2. By Disease Type

        10.2.3. By Drug-class

        10.2.4. By Distribution Channel

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Disease Type

        10.3.3. By Drug-class

        10.3.4. By Distribution Channel

    10.4. Key Takeaways

11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. Germany

            11.2.1.2. United Kingdom

            11.2.1.3. France

            11.2.1.4. Spain

            11.2.1.5. Italy

            11.2.1.6. Rest of Europe

        11.2.2. By Disease Type

        11.2.3. By Drug-class

        11.2.4. By Distribution Channel

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Disease Type

        11.3.3. By Drug-class

        11.3.4. By Distribution Channel

    11.4. Key Takeaways

12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. India

            12.2.1.2. Malaysia

            12.2.1.3. Singapore

            12.2.1.4. Thailand

            12.2.1.5. Rest of South Asia

        12.2.2. By Disease Type

        12.2.3. By Drug-class

        12.2.4. By Distribution Channel

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Disease Type

        12.3.3. By Drug-class

        12.3.4. By Distribution Channel

    12.4. Key Takeaways

13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. China

            13.2.1.2. Japan

            13.2.1.3. South Korea

        13.2.2. By Disease Type

        13.2.3. By Drug-class

        13.2.4. By Distribution Channel

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Disease Type

        13.3.3. By Drug-class

        13.3.4. By Distribution Channel

    13.4. Key Takeaways

14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        14.2.1. By Country

            14.2.1.1. Australia

            14.2.1.2. New Zealand

        14.2.2. By Disease Type

        14.2.3. By Drug-class

        14.2.4. By Distribution Channel

    14.3. Market Attractiveness Analysis

        14.3.1. By Country

        14.3.2. By Disease Type

        14.3.3. By Drug-class

        14.3.4. By Distribution Channel

    14.4. Key Takeaways

15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country

    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022

    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        15.2.1. By Country

            15.2.1.1. GCC Countries

            15.2.1.2. South Africa

            15.2.1.3. Israel

            15.2.1.4. Rest of Middle East and Africa(MEA)

        15.2.2. By Disease Type

        15.2.3. By Drug-class

        15.2.4. By Distribution Channel

    15.3. Market Attractiveness Analysis

        15.3.1. By Country

        15.3.2. By Disease Type

        15.3.3. By Drug-class

        15.3.4. By Distribution Channel

    15.4. Key Takeaways

16. Key Countries Market Analysis

    16.1. USA

        16.1.1. Pricing Analysis

        16.1.2. Market Share Analysis, 2022

            16.1.2.1. By Disease Type

            16.1.2.2. By Drug-class

            16.1.2.3. By Distribution Channel

    16.2. Canada

        16.2.1. Pricing Analysis

        16.2.2. Market Share Analysis, 2022

            16.2.2.1. By Disease Type

            16.2.2.2. By Drug-class

            16.2.2.3. By Distribution Channel

    16.3. Brazil

        16.3.1. Pricing Analysis

        16.3.2. Market Share Analysis, 2022

            16.3.2.1. By Disease Type

            16.3.2.2. By Drug-class

            16.3.2.3. By Distribution Channel

    16.4. Mexico

        16.4.1. Pricing Analysis

        16.4.2. Market Share Analysis, 2022

            16.4.2.1. By Disease Type

            16.4.2.2. By Drug-class

            16.4.2.3. By Distribution Channel

    16.5. Germany

        16.5.1. Pricing Analysis

        16.5.2. Market Share Analysis, 2022

            16.5.2.1. By Disease Type

            16.5.2.2. By Drug-class

            16.5.2.3. By Distribution Channel

    16.6. United Kingdom

        16.6.1. Pricing Analysis

        16.6.2. Market Share Analysis, 2022

            16.6.2.1. By Disease Type

            16.6.2.2. By Drug-class

            16.6.2.3. By Distribution Channel

    16.7. France

        16.7.1. Pricing Analysis

        16.7.2. Market Share Analysis, 2022

            16.7.2.1. By Disease Type

            16.7.2.2. By Drug-class

            16.7.2.3. By Distribution Channel

    16.8. Spain

        16.8.1. Pricing Analysis

        16.8.2. Market Share Analysis, 2022

            16.8.2.1. By Disease Type

            16.8.2.2. By Drug-class

            16.8.2.3. By Distribution Channel

    16.9. Italy

        16.9.1. Pricing Analysis

        16.9.2. Market Share Analysis, 2022

            16.9.2.1. By Disease Type

            16.9.2.2. By Drug-class

            16.9.2.3. By Distribution Channel

    16.10. India

        16.10.1. Pricing Analysis

        16.10.2. Market Share Analysis, 2022

            16.10.2.1. By Disease Type

            16.10.2.2. By Drug-class

            16.10.2.3. By Distribution Channel

    16.11. Malaysia

        16.11.1. Pricing Analysis

        16.11.2. Market Share Analysis, 2022

            16.11.2.1. By Disease Type

            16.11.2.2. By Drug-class

            16.11.2.3. By Distribution Channel

    16.12. Singapore

        16.12.1. Pricing Analysis

        16.12.2. Market Share Analysis, 2022

            16.12.2.1. By Disease Type

            16.12.2.2. By Drug-class

            16.12.2.3. By Distribution Channel

    16.13. Thailand

        16.13.1. Pricing Analysis

        16.13.2. Market Share Analysis, 2022

            16.13.2.1. By Disease Type

            16.13.2.2. By Drug-class

            16.13.2.3. By Distribution Channel

    16.14. China

        16.14.1. Pricing Analysis

        16.14.2. Market Share Analysis, 2022

            16.14.2.1. By Disease Type

            16.14.2.2. By Drug-class

            16.14.2.3. By Distribution Channel

    16.15. Japan

        16.15.1. Pricing Analysis

        16.15.2. Market Share Analysis, 2022

            16.15.2.1. By Disease Type

            16.15.2.2. By Drug-class

            16.15.2.3. By Distribution Channel

    16.16. South Korea

        16.16.1. Pricing Analysis

        16.16.2. Market Share Analysis, 2022

            16.16.2.1. By Disease Type

            16.16.2.2. By Drug-class

            16.16.2.3. By Distribution Channel

    16.17. Australia

        16.17.1. Pricing Analysis

        16.17.2. Market Share Analysis, 2022

            16.17.2.1. By Disease Type

            16.17.2.2. By Drug-class

            16.17.2.3. By Distribution Channel

    16.18. New Zealand

        16.18.1. Pricing Analysis

        16.18.2. Market Share Analysis, 2022

            16.18.2.1. By Disease Type

            16.18.2.2. By Drug-class

            16.18.2.3. By Distribution Channel

    16.19. GCC Countries

        16.19.1. Pricing Analysis

        16.19.2. Market Share Analysis, 2022

            16.19.2.1. By Disease Type

            16.19.2.2. By Drug-class

            16.19.2.3. By Distribution Channel

    16.20. South Africa

        16.20.1. Pricing Analysis

        16.20.2. Market Share Analysis, 2022

            16.20.2.1. By Disease Type

            16.20.2.2. By Drug-class

            16.20.2.3. By Distribution Channel

    16.21. Israel

        16.21.1. Pricing Analysis

        16.21.2. Market Share Analysis, 2022

            16.21.2.1. By Disease Type

            16.21.2.2. By Drug-class

            16.21.2.3. By Distribution Channel

17. Market Structure Analysis

    17.1. Competition Dashboard

    17.2. Competition Benchmarking

    17.3. Market Share Analysis of Top Players

        17.3.1. By Regional

        17.3.2. By Disease Type

        17.3.3. By Drug-class

        17.3.4. By Distribution Channel

18. Competition Analysis

    18.1. Competition Deep Dive

        18.1.1. Teva Pharmaceuticals Ltd.

            18.1.1.1. Overview

            18.1.1.2. Product Portfolio

            18.1.1.3. Profitability by Market Segments

            18.1.1.4. Sales Footprint

            18.1.1.5. Strategy Overview

                18.1.1.5.1. Marketing Strategy

        18.1.2. Zydus Pharmaceuticals, Inc.

            18.1.2.1. Overview

            18.1.2.2. Product Portfolio

            18.1.2.3. Profitability by Market Segments

            18.1.2.4. Sales Footprint

            18.1.2.5. Strategy Overview

                18.1.2.5.1. Marketing Strategy

        18.1.3. Sun Pharmaceuticals Industries Ltd.

            18.1.3.1. Overview

            18.1.3.2. Product Portfolio

            18.1.3.3. Profitability by Market Segments

            18.1.3.4. Sales Footprint

            18.1.3.5. Strategy Overview

                18.1.3.5.1. Marketing Strategy

        18.1.4. Advanz Pharmaceuticals

            18.1.4.1. Overview

            18.1.4.2. Product Portfolio

            18.1.4.3. Profitability by Market Segments

            18.1.4.4. Sales Footprint

            18.1.4.5. Strategy Overview

                18.1.4.5.1. Marketing Strategy

        18.1.5. Novartis AG

            18.1.5.1. Overview

            18.1.5.2. Product Portfolio

            18.1.5.3. Profitability by Market Segments

            18.1.5.4. Sales Footprint

            18.1.5.5. Strategy Overview

                18.1.5.5.1. Marketing Strategy

        18.1.6. Mylan N.V.

            18.1.6.1. Overview

            18.1.6.2. Product Portfolio

            18.1.6.3. Profitability by Market Segments

            18.1.6.4. Sales Footprint

            18.1.6.5. Strategy Overview

                18.1.6.5.1. Marketing Strategy

        18.1.7. Aurobindo Pharma

            18.1.7.1. Overview

            18.1.7.2. Product Portfolio

            18.1.7.3. Profitability by Market Segments

            18.1.7.4. Sales Footprint

            18.1.7.5. Strategy Overview

                18.1.7.5.1. Marketing Strategy

        18.1.8. Dr. Reddy’s Laboratories Ltd.

            18.1.8.1. Overview

            18.1.8.2. Product Portfolio

            18.1.8.3. Profitability by Market Segments

            18.1.8.4. Sales Footprint

            18.1.8.5. Strategy Overview

                18.1.8.5.1. Marketing Strategy

        18.1.9. Viatris Inc.

            18.1.9.1. Overview

            18.1.9.2. Product Portfolio

            18.1.9.3. Profitability by Market Segments

            18.1.9.4. Sales Footprint

            18.1.9.5. Strategy Overview

                18.1.9.5.1. Marketing Strategy

        18.1.10. Pfizer Inc.

            18.1.10.1. Overview

            18.1.10.2. Product Portfolio

            18.1.10.3. Profitability by Market Segments

            18.1.10.4. Sales Footprint

            18.1.10.5. Strategy Overview

                18.1.10.5.1. Marketing Strategy

19. Assumptions & Acronyms Used

20. Research Methodology

Recommendations

Healthcare

Neurodegenerative Disease Market

Published : May 2024

Healthcare

Cardiac Assist Devices Market

Published : June 2023

Healthcare

Cardiac Rhythm Management Market

Published : October 2022

Healthcare

Cardiac Surgery Devices Market

Published : October 2022

Explore Healthcare Insights

View Reports

Andersen Tawil Syndrome Treatment Market